Anesthetic effects in Alzheimer transgenic mouse models

Abstract

Research has improved the diagnosis of Alzheimer's disease, and at earlier stages, but effective therapy continues to be elusive. Current effort is focused on delay. Environmental factors are thought to interact with genetics to modulate the progression of the disease, and one such environmental factor is exposure to general anesthetics. The possibility that some anesthetic effects have long-term consequences is of general interest and concern. The difficulty of studying a chronic, age-related disease in humans combined with the fact that anesthetics are rarely given without surgery, has led to a focus on animal models. Transgenic mouse models have been developed to mimic the hallmarks of Alzheimer's disease, including amyloid beta accumulation (plaque), neurofibrillary tangles, and cognitive dysfunction. While none of the models recapitulate the human disease with high fidelity, they allow a first look at anesthetic-Alzheimer interactions in a reasonable time frame. In studies found to date, none have concluded that anesthetics alone cause a significant change in cognitive decline, but rather an acceleration in Alzheimer neuropathology. Further studies are required to define the best anesthetic paradigm for our elderly population to mitigate changes in neuropathology and potentially cognition.

Keywords: 3xTgAD; AD; APP; APPswe; Alzheimer's disease; Amyloidopathy; Anesthetic sensitivity; Aβ; Desflurane; FAD; Isoflurane; MAC; NFTs; PSEN1; PSEN2; Presenilin-2; Sevoflurane; Tauopathy; amyloid beta; amyloid precursor protein; amyloid precursor protein with the Swedish mutation; familial Alzheimer's disease; minimum alveolar concentration; neurofibrillary tangles; presenilin-1; triple transgenic AD mouse model.